Author

Tushar D. Nichakawade

Johns Hopkins UniversityORCID 0000-0002-4091-7580Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Synthetic Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

Bum Seok LeeiD· 2 shared Evangeline Watson· 2 shared Suman PauliD· 2 shared Taha S. AhmednaiD· 2 shared Alexander H. PearlmaniD· 1 shared Amy Elizabeth DezerniD· 1 shared Bert VogelsteiniD· 1 shared Bogdan C. Paun· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSynthetic Biology

Bum Seok LeeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Spatial Regulation of CAR Signaling Enables Logic-Gated Activity

Tushar D. Nichakawade, Brian J. Mog, Alexander H. Pearlman, Taha S. Ahmedna, Nikita Marcou, Ricardo Mora-Cartín, Evangeline Watson, Bum Seok Lee, Sarah R. DiNapoli, Nickolas Papadopoulos, Chetan Bettegowda, Marco Dal Molin, Denis Wirtz, Drew M. Pardoll, Suman Paul, , Kenneth W. Kinzler

The paper designs an AND-gated CAR T cell receptor called MANTIS that uses extracellular size differences to spatially regulate signaling for precise antigen recognition.

bioRxiv · May 24, 2026 · PreprintSynthetic Biology

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML

Nour Sabiha Naji, Taha S. Ahmedna, J. David Peske, Xinghan Zeng, Brandy N. Perkins, Zanshé Thompson, Tushar D. Nichakawade, Bum Seok Lee, Evangeline Watson, Theodora Chatzilygeroudi, Li Luo, Bogdan C. Paun, Melanie Klausner, Yuju An, Teodora Supeanu, , Theodoros Karantanos

This paper develops an anti-CCRL2 antibody-drug conjugate (ADC) that shows potent cytotoxicity against high-risk MDS/AML cells without harming healthy hematopoietic cells.

bioRxiv · Aug 17, 2025 · PreprintCancer Biology